News

AOD-9604 vs. Semaglutide: Bone Loss Risk in Menopausal Weight Loss
Comparing AOD-9604 and semaglutide for menopausal weight loss reveals distinct mechanisms but similar bone loss risks. Research quality remains limited for both compounds in this population. Read more...
Semaglutide and Bone Health: Does GLP-1 Therapy Reduce Fracture Risk During Weight Loss?
Exploring the relationship between semaglutide (Ozempic/Wegovy) and bone health: what research reveals about fracture risk during GLP-1-assisted weight loss. Read more...